Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 289 articles:
HTML format



Single Articles


    June 2022
  1. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    PubMed     Abstract available


  2. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    PubMed     Abstract available


  3. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    PubMed    


  4. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    PubMed    


    May 2022
  5. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    PubMed    


  6. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    PubMed    


  7. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    PubMed    


  8. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    PubMed    


  9. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.
    PubMed    


    April 2022
  10. ADEPOJU P
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.
    PubMed    


  11. NGUYEN-TRAN H, Messacar K
    Preventing enterovirus A71 disease: another promising vaccine for children.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00380.
    PubMed    


  12. NGUYEN TT, Chiu CH, Lin CY, Chiu NC, et al
    Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00313.
    PubMed     Abstract available


  13. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.
    PubMed    


  14. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.
    PubMed    


  15. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    PubMed     Abstract available


  16. WINTER AK, Moss WJ
    Rubella.
    Lancet. 2022;399:1336-1346.
    PubMed     Abstract available


  17. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
    Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
    Lancet. 2022;399:1313-1321.
    PubMed     Abstract available


  18. BLAKNEY AK, Bekker LG
    DNA vaccines join the fight against COVID-19.
    Lancet. 2022;399:1281-1282.
    PubMed    


    March 2022
  19. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
    Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
    Lancet. 2022;399:1225.
    PubMed    


  20. NIXON DF, Schwartz RE, Ndhlovu LC
    Booster vaccines for COVID-19 vaccine breakthrough cases?
    Lancet. 2022;399:1224.
    PubMed    


  21. BEKKER LG, Garrett N, Goga A, Fairall L, et al
    Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Lancet. 2022;399:1141-1153.
    PubMed     Abstract available


  22. USHER AD
    CEPI launches 100-day vaccine "moonshot".
    Lancet. 2022;399:1107-1108.
    PubMed    


  23. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
    Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
    PubMed     Abstract available


  24. MILLS EJ, Reis G
    Evaluating COVID-19 vaccines in the real world.
    Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.
    PubMed    


  25. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    PubMed    


  26. FALLAH MP, Reinhart E
    Apartheid logic in global health.
    Lancet. 2022;399:902-903.
    PubMed    


  27. NUNEZ I
    Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.
    Lancet. 2022 Mar 2. pii: S0140-6736(22)00164.
    PubMed    


    February 2022
  28. CHEMAITELLY H, Abu-Raddad LJ
    Waning effectiveness of COVID-19 vaccines.
    Lancet. 2022;399:771-773.
    PubMed    



  29. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
    PubMed     Abstract available


  30. BAJAJ SS, Maki L, Stanford FC
    Vaccine apartheid: global cooperation and equity.
    Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.
    PubMed    


  31. PIECHOTTA V, Harder T
    Waning of COVID-19 vaccine effectiveness: individual and public health risk.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00282.
    PubMed    


  32. FEIKIN DR, Higdon MM, Abu-Raddad LJ, Andrews N, et al
    Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
    Lancet. 2022 Feb 21. pii: S0140-6736(22)00152.
    PubMed     Abstract available


  33. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    PubMed    


  34. MADHI SA, Ihekweazu C, Rees H, Pollard AJ, et al
    Decoupling of omicron variant infections and severe COVID-19.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00109.
    PubMed    


  35. EGGER S, Egger G
    The vaccinated propor-tion of people with COVID-19 needs context.
    Lancet. 2022;399:627.
    PubMed    


  36. CAPLAN AL
    Stigma, vaccination, and moral accountability.
    Lancet. 2022;399:626-627.
    PubMed    


  37. SAMARASEKERA U
    Ayoade Alakija: advancing equity in the COVID-19 response.
    Lancet. 2022;399:511.
    PubMed    


  38. BURKI T
    Fresh questions over Gates Foundation governance.
    Lancet. 2022;399:508.
    PubMed    


  39. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    PubMed    


  40. NORDSTROM P, Ballin M, Nordstrom A
    Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
    Lancet. 2022 Feb 4. pii: S0140-6736(22)00089.
    PubMed     Abstract available


  41. KARAFILLAKIS E, Van Damme P, Hendrickx G, Larson HJ, et al
    COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
    Lancet. 2022 Feb 3. pii: S0140-6736(22)00150.
    PubMed    



  42. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    Lancet. 2022 Feb 1. pii: S0140-6736(22)00172.
    PubMed     Abstract available


    January 2022
  43. JAFFE S
    The next steps for US vaccine mandates.
    Lancet. 2022;399:425-426.
    PubMed    



  44. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
    Lancet. 2022 Jan 27. pii: S0140-6736(22)00101.
    PubMed     Abstract available


  45. HUBSCHEN JM, Gouandjika-Vasilache I, Dina J
    Measles.
    Lancet. 2022 Jan 27. pii: S0140-6736(21)02004.
    PubMed     Abstract available


  46. FENDLER A, Shepherd STC, Au L, Wu M, et al
    Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
    Lancet. 2022 Jan 25. pii: S0140-6736(22)00147.
    PubMed    


  47. LANE R
    Jamal Rifi: family doctor building bridges in the community.
    Lancet. 2022;399:353.
    PubMed    


  48. COSTA CLEMENS SA, Weckx L, Clemens R, Almeida Mendes AV, et al
    Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00094.
    PubMed     Abstract available


  49. BRAVO L, Smolenov I, Han HH, Li P, et al
    Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00055.
    PubMed     Abstract available


  50. VESIKARI T
    Trimeric S protein COVID-19 vaccine needs to find its place.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00096.
    PubMed    


  51. CARR EJ, Wu M, Harvey R, Billany RE, et al
    Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
    Lancet. 2022 Jan 20. pii: S0140-6736(22)00104.
    PubMed    


  52. WU M, Wall EC, Carr EJ, Harvey R, et al
    Three-dose vaccination elicits neutralising antibodies against omicron.
    Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.
    PubMed    


  53. KUHLMANN C, Mayer CK, Claassen M, Maponga T, et al
    Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00090.
    PubMed    


    December 2021
  54. KING J, Ferraz OLM, Jones A
    Mandatory COVID-19 vaccination and human rights.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02873.
    PubMed    


  55. HALPERIN SA, Ye L, MacKinnon-Cameron D, Smith B, et al
    Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02753.
    PubMed     Abstract available


  56. KENNEDY RB
    Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.
    Lancet. 2021 Dec 23. pii: S0140-6736(21)02834.
    PubMed    


  57. LEUNG K, Wu JT
    Managing waning vaccine protection against SARS-CoV-2 variants.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02841.
    PubMed    


  58. KATIKIREDDI SV, Cerqueira-Silva T, Vasileiou E, Robertson C, et al
    Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02754.
    PubMed     Abstract available


  59. PEELING RW, Heymann DL, Teo YY, Garcia PJ, et al
    Diagnostics for COVID-19: moving from pandemic response to control.
    Lancet. 2021 Dec 20. pii: S0140-6736(21)02346.
    PubMed     Abstract available


  60. MCINTYRE PB, Aggarwal R, Jani I, Jawad J, et al
    COVID-19 vaccine strategies must focus on severe disease and global equity.
    Lancet. 2021 Dec 16. pii: S0140-6736(21)02835.
    PubMed    


  61. STUART ASV, Shaw RH, Liu X, Greenland M, et al
    Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02718.
    PubMed     Abstract available


  62. RICHARDSON CD
    Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19.
    Lancet. 2021 Dec 6. pii: S0140-6736(21)02757.
    PubMed    


  63. KARIM SSA, Karim QA
    Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02758.
    PubMed    


  64. MENDELSON M, Venter F, Moshabela M, Gray G, et al
    The political theatre of the UK's travel ban on South Africa.
    Lancet. 2021 Dec 3. pii: S0140-6736(21)02752.
    PubMed    


  65. MUNRO APS, Janani L, Cornelius V, Aley PK, et al
    Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Lancet. 2021 Dec 2. pii: S0140-6736(21)02717.
    PubMed     Abstract available


    November 2021
  66. JAFFE S
    Legal challenges threaten Biden's COVID-19 vaccine rule.
    Lancet. 2021;398:1863-1864.
    PubMed    


  67. BURKI T
    mRNA discoveries earn the 2021 Prince Mahidol Award.
    Lancet. 2021;398:1865.
    PubMed    


  68. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
    Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
    PubMed     Abstract available


  69. PAVORD S, Scully M, Lester W, Makris M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
    Lancet. 2021;398:1801.
    PubMed    


  70. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
    Lancet. 2021;398:1801-1802.
    PubMed    


  71. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
    Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
    PubMed     Abstract available


  72. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
    Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
    PubMed     Abstract available


  73. LI JX, Zhu FC
    Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
    Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.
    PubMed    


  74. ALVES L
    Health experts welcome Brazil COVID-19 inquiry findings.
    Lancet. 2021;398:1674-1675.
    PubMed    


  75. USHER AD
    New budget and strategy for ACT-A.
    Lancet. 2021;398:1677.
    PubMed    


  76. ZAROCOSTAS J
    WHO's Tedros set to be re-elected unopposed.
    Lancet. 2021;398:1676.
    PubMed    


  77. ORTIZ JR, Neuzil KM
    The value of vaccine programme impact monitoring during the COVID-19 pandemic.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.
    PubMed    


  78. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
    Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
    PubMed     Abstract available


  79. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available


    October 2021
  80. HODGES S, Hornberger J, Kufakurinani U, Rudra S, et al
    When suspicion replaces evidence in public health.
    Lancet. 2021;398:1565-1566.
    PubMed    


  81. BARDA N, Dagan N, Cohen C, Hernan MA, et al
    Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
    Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
    PubMed     Abstract available


  82. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
    Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
    Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.
    PubMed    


  83. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    PubMed     Abstract available


  84. USHER AD
    Vaccine shortages prompt changes to COVAX strategy.
    Lancet. 2021;398:1474.
    PubMed    


  85. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
    Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
    Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.
    PubMed    


  86. SAMARASEKERA U
    Cautious optimism for malaria vaccine roll-out.
    Lancet. 2021;398:1394.
    PubMed    


  87. SAAG MS
    Developing COVID-19 vaccine policy in increments.
    Lancet. 2021;398:1382-1383.
    PubMed    


  88. THE LANCET
    Malaria vaccine approval: a step change for global health.
    Lancet. 2021;398:1381.
    PubMed    


  89. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
    Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.
    PubMed    


  90. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
    Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
    PubMed     Abstract available


    September 2021
  91. THE LANCET
    COVID-19: learning as an interdependent world.
    Lancet. 2021;398:1105.
    PubMed    


  92. SHARFSTEIN JM, Callaghan T, Carpiano RM, Sgaier SK, et al
    Uncoupling vaccination from politics: a call to action.
    Lancet. 2021 Sep 16. pii: S0140-6736(21)02099.
    PubMed    


  93. KRAUSE PR, Fleming TR, Peto R, Longini IM, et al
    Considerations in boosting COVID-19 vaccine immune responses.
    Lancet. 2021 Sep 14. pii: S0140-6736(21)02046.
    PubMed    


  94. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    PubMed    


  95. BOSELEY S
    The race to make a COVID-19 vaccine.
    Lancet. 2021;398:832-833.
    PubMed    


  96. JERVING S
    The long road ahead for COVID-19 vaccination in Africa.
    Lancet. 2021;398:827-828.
    PubMed    


  97. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
    Community-acquired pneumonia.
    Lancet. 2021;398:906-919.
    PubMed     Abstract available


  98. ROGAWSKI MCQUADE ET, Breskin A
    Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01817.
    PubMed    


  99. KASEJE N, Walcott D
    Global youth advocating for COVID-19 vaccines for all.
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01994.
    PubMed    


  100. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
    Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
    Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
    PubMed     Abstract available


    August 2021
  101. LANGLOIS EV, Dey T, Shah MG
    More than honour, humanitarian health-care workers need life-saving protection.
    Lancet. 2021;398:729-730.
    PubMed    


  102. USHER AD
    Health leaders criticise limited ACT-A review.
    Lancet. 2021;398:650-651.
    PubMed    


  103. BEHRENS GM, Cossmann A, Stankov MV, Nehlmeier I, et al
    SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.
    Lancet. 2021 Aug 17. pii: S0140-6736(21)01891.
    PubMed    


  104. DANIELS JP
    Haiti's health woes intensify.
    Lancet. 2021;398:567.
    PubMed    


  105. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
    Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.
    Lancet. 2021;398:577-578.
    PubMed    


  106. CARR EJ, Wu M, Harvey R, Wall EC, et al
    Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
    Lancet. 2021 Aug 12. pii: S0140-6736(21)01854.
    PubMed    


  107. LLOYD-SHERLOCK P, Lasco G, McKee M, Perianayagam A, et al
    Does vaccine ageism amount to gerontocide?
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01689.
    PubMed    


  108. KALAFAT E, Magee LA, von Dadelszen P, O'Brien P, et al
    SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity.
    Lancet. 2021 Aug 11. pii: S0140-6736(21)01756.
    PubMed    


  109. CRUMP JA, Oo WT
    Salmonella Typhi Vi polysaccharide conjugate vaccine protects infants and children against typhoid fever.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01340.
    PubMed    


  110. QADRI F, Khanam F, Liu X, Theiss-Nyland K, et al
    Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01124.
    PubMed     Abstract available


  111. PRIESEMANN V, Balling R, Bauer S, Beutels P, et al
    Towards a European strategy to address the COVID-19 pandemic.
    Lancet. 2021 Aug 9. pii: S0140-6736(21)01808.
    PubMed    


  112. LEE EJ, Lee AI
    Cerebral venous sinus thrombosis after vaccination: the UK experience.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01788.
    PubMed    


  113. PERRY RJ, Tamborska A, Singh B, Craven B, et al
    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01608.
    PubMed     Abstract available


  114. LIU X, Shaw RH, Stuart ASV, Greenland M, et al
    Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01694.
    PubMed     Abstract available


  115. BELDA-INIESTA C
    Optimising SARS-CoV-2 vaccination schedules.
    Lancet. 2021 Aug 6. pii: S0140-6736(21)01729.
    PubMed    


    July 2021
  116. SHROTRI M, Navaratnam AMD, Nguyen V, Byrne T, et al
    Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
    Lancet. 2021;398:385-387.
    PubMed    


  117. KAMPMANN B, Okomo U
    COVID-19 vaccines for children in LMICs: another equity issue.
    Lancet. 2021 Jul 30. pii: S0140-6736(21)01748.
    PubMed    


  118. MAKONI M
    Social unrest disrupts South African health care.
    Lancet. 2021;398:287.
    PubMed    


  119. REDJOUL R, Le Bouter A, Beckerich F, Fourati S, et al
    Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
    Lancet. 2021;398:298-299.
    PubMed    


  120. THE LANCET
    COVID-19 in Africa: a lesson in solidarity.
    Lancet. 2021;398:185.
    PubMed    


  121. DANOVARO-HOLLIDAY MC, Kretsinger K, Gacic-Dobo M
    Measuring and ensuring routine childhood vaccination coverage.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01228.
    PubMed    


  122. CAUCHEMEZ S, Bosetti P, Kiem CT, Mouro V, et al
    Education and mental health: good reasons to vaccinate children.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01453.
    PubMed    


  123. CAUSEY K, Fullman N, Sorensen RJD, Galles NC, et al
    Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01337.
    PubMed     Abstract available



  124. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00984.
    PubMed     Abstract available


  125. THE LANCET
    COVID-19 in Latin America-emergency and opportunity.
    Lancet. 2021;398:93.
    PubMed    


  126. TANRIOVER MD, Doganay HL, Akova M, Guner HR, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Lancet. 2021 Jul 8. pii: S0140-6736(21)01429.
    PubMed     Abstract available


  127. GURDASANI D, Drury J, Greenhalgh T, Griffin S, et al
    Mass infection is not an option: we must do more to protect our young.
    Lancet. 2021 Jul 7. pii: S0140-6736(21)01589.
    PubMed    


  128. KICKBUSCH I, Leung GM, Shattock RJ
    Learning from crisis: building resilient systems to combat future pandemics.
    Lancet. 2021;398:e2-e6.
    PubMed    


    June 2021
  129. WALL EC, Wu M, Harvey R, Kelly G, et al
    AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
    Lancet. 2021 Jun 28. pii: S0140-6736(21)01462.
    PubMed    


  130. DANIELS JP
    Colombians protest over inequities and health care.
    Lancet. 2021;397:2454.
    PubMed    


  131. SMITH MJ
    What constitutes success in the roll-out of COVID-19 vaccines?
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01244.
    PubMed    


  132. DUARTE-SALLES T, Prieto-Alhambra D
    Heterologous vaccine regimens against COVID-19.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01442.
    PubMed    


  133. BOROBIA AM, Carcas AJ, Perez-Olmeda M, Castano L, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01420.
    PubMed     Abstract available


  134. THE LANCET
    Protecting refugees during the COVID-19 pandemic.
    Lancet. 2021;397:2309.
    PubMed    


  135. USHER AD
    A beautiful idea: how COVAX has fallen short.
    Lancet. 2021;397:2322-2325.
    PubMed    


  136. ABECASSIS A
    Five priorities for universal COVID-19 vaccination.
    Lancet. 2021 Jun 17. pii: S0140-6736(21)01371.
    PubMed    


  137. SHEIKH A, McMenamin J, Taylor B, Robertson C, et al
    SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
    Lancet. 2021 Jun 14. pii: S0140-6736(21)01358.
    PubMed    


  138. GAYTHORPE KAM, Toor J, Echeverria-Londono S, Li X, et al
    Vaccines can save children with non-preventable diseases - Authors' reply.
    Lancet. 2021;397:2251.
    PubMed    


  139. SAHA S, Saha SK
    Vaccines can save children with non-preventable diseases.
    Lancet. 2021;397:2250.
    PubMed    


  140. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply.
    Lancet. 2021;397:2249-2250.
    PubMed    


  141. ROBERTSON JFR, Sewell HF
    COVID-19 vaccine efficacy data: solid enough to delay second dose?
    Lancet. 2021;397:2248-2249.
    PubMed    


  142. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.
    Lancet. 2021;397:2248.
    PubMed    


  143. MCQUADE ETR, Platts-Mills JA
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
    Lancet. 2021;397:2247-2248.
    PubMed    


  144. NASSER A, Zakham F
    A strategy for SARS-CoV-2 vaccination in Yemen.
    Lancet. 2021;397:2247.
    PubMed    


  145. GUETL K, Gary T, Raggam RB, Schmid J, et al
    SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.
    Lancet. 2021 Jun 11. pii: S0140-6736(21)01238.
    PubMed    


  146. BOLLYKY TJ, Murray CJL, Reiner RC Jr
    Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.
    Lancet. 2021 Jun 8. pii: S0140-6736(21)01323.
    PubMed    


  147. KUMAR A, Bernasconi V, Manak M, de Almeida Aranha AP, et al
    The CEPI centralised laboratory network: supporting COVID-19 vaccine development.
    Lancet. 2021;397:2148-2149.
    PubMed    


  148. USHER AD
    ACT Accelerator strains donors' aid budgets.
    Lancet. 2021;397:2137.
    PubMed    


  149. WALL EC, Wu M, Harvey R, Kelly G, et al
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01290.
    PubMed    


  150. NNAJI CA, Ndwandwe D, Lesosky M, Mahomed H, et al
    Tackling missed opportunities for vaccination in a new era of immunisation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01226.
    PubMed    


  151. KOSAKA M, Hashimoto T, Ozaki A, Tanimoto T, et al
    Delayed COVID-19 vaccine roll-out in Japan.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01220.
    PubMed    


  152. FORMAN R, Jit M, Mossialos E
    Divergent vaccination policies could fuel mistrust and hesitancy.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)01106.
    PubMed    


    May 2021
  153. MAKONI M
    Africa's need for more COVID-19 clinical trials.
    Lancet. 2021;397:2037.
    PubMed    


  154. JAWAD NK, Taweeleh LA, Elharake JA, Khamis N, et al
    Refugee access to COVID-19 vaccines in Lebanon.
    Lancet. 2021;397:1884.
    PubMed    


  155. ZAROCOSTAS J
    What next for a COVID-19 intellectual property waiver?
    Lancet. 2021;397:1871-1872.
    PubMed    


  156. LOYO ESL, Gonzalez MJ, Esparza J
    Venezuela is collapsing without COVID-19 vaccines.
    Lancet. 2021;397:1806.
    PubMed    


  157. WATSON SI
    Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?
    Lancet. 2021;397:1804-1805.
    PubMed    


  158. TORRES I, Lopez-Cevallos D, Artaza O, Profeta B, et al
    Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments.
    Lancet. 2021;397:1804.
    PubMed    


  159. HOUSTON AR, Murthy S
    Canada is no global health leader on COVID-19 vaccine equity.
    Lancet. 2021;397:1803.
    PubMed    


  160. HOLT E
    Serbia begins paying citizens to receive a COVID-19 vaccine.
    Lancet. 2021;397:1793.
    PubMed    


  161. GENC K
    COVID-19 in Turkey: a nation on edge.
    Lancet. 2021;397:1794-1796.
    PubMed    


  162. JHA P, Jamison DT, Watkins DA, Bell J, et al
    A global compact to counter vaccine nationalism.
    Lancet. 2021 May 14. pii: S0140-6736(21)01105.
    PubMed    


  163. KUPPALLI K, Gala P, Cherabuddi K, Kalantri SP, et al
    India's COVID-19 crisis: a call for international action.
    Lancet. 2021 May 14. pii: S0140-6736(21)01121.
    PubMed    


  164. SHAW RH, Stuart A, Greenland M, Liu X, et al
    Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Lancet. 2021 May 12. pii: S0140-6736(21)01115.
    PubMed    


  165. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV
    Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.
    Lancet. 2021 May 12. pii: S0140-6736(21)00894.
    PubMed    


  166. SAXENA SG, Godfrey T
    Catalysing needed change for health systems in the USA.
    Lancet. 2021;397:1705-1706.
    PubMed    


  167. REINHART E, Dawes D, Maybank A
    Structural medicine: towards an economy of care.
    Lancet. 2021;397:1691-1693.
    PubMed    


  168. MOORTHY V, Binka F
    R21/Matrix-M: a second malaria vaccine?
    Lancet. 2021 May 5. pii: S0140-6736(21)01065.
    PubMed    


  169. DATOO MS, Natama MH, Some A, Traore O, et al
    Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Lancet. 2021 May 5. pii: S0140-6736(21)00943.
    PubMed     Abstract available


  170. HAAS EJ, Angulo FJ, McLaughlin JM, Anis E, et al
    Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Lancet. 2021 May 5. pii: S0140-6736(21)00947.
    PubMed     Abstract available


  171. LESHEM E, Wilder-Smith A
    COVID-19 vaccine impact in Israel and a way out of the pandemic.
    Lancet. 2021 May 5. pii: S0140-6736(21)01018.
    PubMed    


  172. BHUYAN A
    Experts criticise India's complacency over COVID-19.
    Lancet. 2021;397:1611-1612.
    PubMed    


    April 2021
  173. BURKI T
    Statelessness in the COVID-19 pandemic.
    Lancet. 2021;397:1529-1530.
    PubMed    


  174. THE LANCET
    2021: the beginning of a new era of immunisations?
    Lancet. 2021;397:1519.
    PubMed    


  175. HALL VJ, Foulkes S, Saei A, Andrews N, et al
    COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00790.
    PubMed     Abstract available


  176. LESHEM E, Lopman BA
    Population immunity and vaccine protection against infection.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00870.
    PubMed    


  177. DEAN N
    Hospital admissions due to COVID-19 in Scotland after one dose of vaccine.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00765.
    PubMed    


  178. VASILEIOU E, Simpson CR, Shi T, Kerr S, et al
    Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00677.
    PubMed     Abstract available


  179. KHAN MS, Ali SAM, Adelaine A, Karan A, et al
    Rethinking vaccine hesitancy among minority groups.
    Lancet. 2021 Apr 21. pii: S0140-6736(21)00938.
    PubMed    


  180. ALVES L
    Brazilian ICUs short of drugs and beds amid COVID-19 surge.
    Lancet. 2021;397:1431-1432.
    PubMed    


  181. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    PubMed    


  182. MUSTER V, Gary T, Raggam RB, WOlfler A, et al
    Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00871.
    PubMed    


  183. MFINANGA SG, Mnyambwa NP, Minja DT, Ntinginya NE, et al
    Tanzania's position on the COVID-19 pandemic.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00678.
    PubMed    


  184. CAPUA I, Giaquinto C
    The unsung virtue of thermostability.
    Lancet. 2021;397:1346.
    PubMed    


  185. ALI SN, Hanif W, Patel K, Khunti K, et al
    Ramadan and COVID-19 vaccine hesitancy-a call for action.
    Lancet. 2021 Apr 7. pii: S0140-6736(21)00779.
    PubMed    


  186. D'SOUZA RS, Wolfe I
    COVID-19 vaccines in high-risk ethnic groups.
    Lancet. 2021 Apr 1. pii: S0140-6736(21)00624.
    PubMed    


    March 2021
  187. EMARY KRW, Golubchik T, Aley PK, Ariani CV, et al
    Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00628.
    PubMed     Abstract available


  188. OSTERGAARD SD, Schmidt M, Horvath-Puho E, Thomsen RW, et al
    Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00762.
    PubMed    


  189. SANDERS RW, de Jong MD
    Pandemic moves and countermoves: vaccines and viral variants.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00730.
    PubMed    


  190. MYLAN S, Hardman C
    COVID-19, cults, and the anti-vax movement.
    Lancet. 2021;397:1181.
    PubMed    


  191. USHER AD
    Uncertainties over EU COVID-19 vaccine sharing scheme.
    Lancet. 2021;397:1171.
    PubMed    


  192. KLUGE H, McKee M
    COVID-19 vaccines for the European region: an unprecedented challenge.
    Lancet. 2021 Mar 25. pii: S0140-6736(21)00709.
    PubMed    



  193. Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00708.
    PubMed    


  194. CHANDAN JS, Chandan JK
    Considering gender-based violence in vaccine prioritisation strategies.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00532.
    PubMed    


  195. KRISTIANSEN PA, Page M, Bernasconi V, Mattiuzzo G, et al
    WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
    Lancet. 2021 Mar 23. pii: S0140-6736(21)00527.
    PubMed    


  196. KARIM SSA
    Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00468.
    PubMed    


  197. MUNDT AP
    Assessing government responsibility for COVID-19 deaths.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00529.
    PubMed    


  198. SAAH AJ, Munoz N
    Control vaccine formulation - Authors' reply.
    Lancet. 2021;397:1062.
    PubMed    


  199. DOSHI P, Hong K, Jefferson T, Jones M, et al
    Control vaccine formulation.
    Lancet. 2021;397:1061-1062.
    PubMed    


  200. JAFFE S
    Biden's first legislative victory: $1.9 trillion for COVID-19.
    Lancet. 2021;397:1047-1048.
    PubMed    


  201. THE LANCET
    Myanmar's democracy and health on life support.
    Lancet. 2021;397:1035.
    PubMed    


  202. BOZORGMEHR K, Jahn R, Stuckler D, McKee M, et al
    Free licensing of vaccines to end the COVID-19 crisis.
    Lancet. 2021 Mar 18. pii: S0140-6736(21)00467.
    PubMed    


  203. KRIEGER N, Waterman PD, Chen JT, Testa C, et al
    Missing again: US racial and ethnic data for COVID-19 vaccination.
    Lancet. 2021 Mar 17. pii: S0140-6736(21)00465.
    PubMed    


  204. HOLT E
    Countries split from EU on COVID-19 vaccines.
    Lancet. 2021;397:958.
    PubMed    


  205. THE LANCET
    Access to COVID-19 vaccines: looking beyond COVAX.
    Lancet. 2021;397:941.
    PubMed    


  206. DEVI S
    Health in Syria: a decade of conflict.
    Lancet. 2021;397:955-956.
    PubMed    


  207. STEINBERG J, Thomas A, Iravani A
    (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
    Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.
    PubMed    


  208. SAMARASEKERA U
    Robin Shattock: novel vaccine developer.
    Lancet. 2021;397:870.
    PubMed    


  209. HUNG IFN, Poland GA
    Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
    Lancet. 2021;397:854-855.
    PubMed    


  210. VIJAYASINGHAM L, Bischof E, Wolfe J
    Sex-disaggregated data in COVID-19 vaccine trials.
    Lancet. 2021 Mar 5. pii: S0140-6736(21)00384.
    PubMed    


    February 2021
  211. BATNIJI R
    Historical evidence to inform COVID-19 vaccine mandates.
    Lancet. 2021;397:791.
    PubMed    


  212. CHAUVIN L
    Peruvian COVID-19 vaccine scandal spreads.
    Lancet. 2021;397:783.
    PubMed    


  213. ZAROCOSTAS J
    New WTO leader faces COVID-19 challenges.
    Lancet. 2021;397:782.
    PubMed    


  214. ADEPOJU P
    Ebola returns to Guinea and DR Congo.
    Lancet. 2021;397:781.
    PubMed    


  215. PRENDECKI M, Clarke C, Brown J, Cox A, et al
    Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00502.
    PubMed    


  216. MANISTY C, Otter AD, Treibel TA, McKnight A, et al
    Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00501.
    PubMed    



  217. Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Feb 24. pii: S0140-6736(21)00372.
    PubMed    


  218. SIVA N
    Severe mental illness: reassessing COVID-19 vaccine priorities.
    Lancet. 2021;397:657.
    PubMed    


  219. HYDE R
    von der Leyen admits to COVID-19 vaccine failures.
    Lancet. 2021;397:655-656.
    PubMed    


  220. VOYSEY M, Costa Clemens SA, Madhi SA, Weckx LY, et al
    Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00432.
    PubMed     Abstract available


  221. SISA I, Noblecilla E, Orozco F
    Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00357.
    PubMed    


  222. ROBERTSON JFR, Sewell HF, Stewart M
    Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00455.
    PubMed    


  223. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
    Lancet. 2021 Feb 18. pii: S0140-6736(21)00448.
    PubMed    


  224. SKEGG D, Gluckman P, Boulton G, Hackmann H, et al
    Future scenarios for the COVID-19 pandemic.
    Lancet. 2021 Feb 16. pii: S0140-6736(21)00424.
    PubMed    


  225. MAKONI M
    Tanzania refuses COVID-19 vaccines.
    Lancet. 2021;397:566.
    PubMed    


  226. THE LANCET
    Improving prisoner health for stronger public health.
    Lancet. 2021;397:555.
    PubMed    


  227. WOUTERS OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, et al
    Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00306.
    PubMed     Abstract available



  228. Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00388.
    PubMed    


  229. FONTANET A, Autran B, Lina B, Kieny MP, et al
    SARS-CoV-2 variants and ending the COVID-19 pandemic.
    Lancet. 2021 Feb 11. pii: S0140-6736(21)00370.
    PubMed    


  230. MARTIN S, Arawi T
    Ensure Palestinians have access to COVID-19 vaccines.
    Lancet. 2021 Feb 9. pii: S0140-6736(21)00190.
    PubMed    


  231. BEHRENS RH, Patel V
    Avoiding shoulder injury from intramuscular vaccines.
    Lancet. 2021;397:471.
    PubMed    


  232. WARRELL MJ
    Time to revise the strategy for Gavi funding of rabies vaccine?
    Lancet. 2021;397:471-472.
    PubMed    


  233. LANE R
    Tahmeed Ahmed: new leader of icddr,b.
    Lancet. 2021;397:463.
    PubMed    


  234. LOIZIDES U, Adisa A, de la Rica Manjavacas AL, Robertson JS, et al
    WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00099.
    PubMed    


  235. MEREWOOD A, Bode L, Davanzo R, Perez-Escamilla R, et al
    Breastfeed or be vaccinated-an unreasonable default recommendation.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00197.
    PubMed    


  236. CLARFIELD AM, Skorecki K, Manor O, Glick S, et al
    A COVID-19 jab in the right direction.
    Lancet. 2021 Feb 4. pii: S0140-6736(21)00310.
    PubMed    


  237. JONES I, Roy P
    Sputnik V COVID-19 vaccine candidate appears safe and effective.
    Lancet. 2021 Feb 2. pii: S0140-6736(21)00191.
    PubMed    


  238. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, et al
    Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
    Lancet. 2021 Feb 2. pii: S0140-6736(21)00234.
    PubMed     Abstract available


  239. FRIESEN P, Caplan AL, Miller JE
    COVID-19 vaccine research and the trouble with clinical equipoise.
    Lancet. 2021 Feb 1. pii: S0140-6736(21)00198.
    PubMed    


    January 2021
  240. LI X, Mukandavire C, Cucunuba ZM, Echeverria Londono S, et al
    Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
    Lancet. 2021;397:398-408.
    PubMed     Abstract available


  241. DANIELS JP
    Health experts slam Bolsonaro's vaccine comments.
    Lancet. 2021;397:361.
    PubMed    


  242. COHEN AL, Patel MK, Cherian T
    Vaccines work: a reason for celebration and renewed commitment.
    Lancet. 2021;397:351-353.
    PubMed    


  243. THE LANCET
    Health and care workers are owed a better future.
    Lancet. 2021;397:347.
    PubMed    


  244. BLAKNEY AK, McKay PF
    Next-generation COVID-19 vaccines: here come the proteins.
    Lancet. 2021 Jan 29. pii: S0140-6736(21)00258.
    PubMed    


  245. RICHMOND P, Hatchuel L, Dong M, Ma B, et al
    Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Lancet. 2021 Jan 29. pii: S0140-6736(21)00241.
    PubMed     Abstract available



  246. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
    Lancet. 2021 Jan 28. pii: S0140-6736(21)00242.
    PubMed    


  247. WATT G, Giacaman R, Zurayk H, Bjertness E, et al
    COVID-19 vaccines for Palestinians.
    Lancet. 2021 Jan 28. pii: S0140-6736(21)00185.
    PubMed    


  248. BARDAJI A, Sevene E, Cutland C, Menendez C, et al
    The need for a global COVID-19 maternal immunisation research plan.
    Lancet. 2021 Jan 25. pii: S0140-6736(21)00146.
    PubMed    


  249. BHUYAN A
    India begins COVID-19 vaccination amid trial allegations.
    Lancet. 2021;397:264.
    PubMed    


  250. MAKONI M
    South Africa responds to new SARS-CoV-2 variant.
    Lancet. 2021;397:267.
    PubMed    


  251. USHER AD
    CEPI criticised for lack of transparency.
    Lancet. 2021;397:265-266.
    PubMed    


  252. CAVALERI M, Enzmann H, Straus S, Cooke E, et al
    The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
    Lancet. 2021 Jan 13. pii: S0140-6736(21)00085.
    PubMed    


  253. STAPLES JE, Alvarez AR
    Public health role for fractional dosage of yellow fever vaccine.
    Lancet. 2021;397:76-77.
    PubMed    


  254. JUAN-GINER A, Kimathi D, Grantz KH, Hamaluba M, et al
    Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Lancet. 2021;397:119-127.
    PubMed     Abstract available


  255. GOSTIN LO, Shalala DE, Hamburg MA, Bloom BR, et al
    A global health action agenda for the Biden administration.
    Lancet. 2021;397:5-8.
    PubMed    


    December 2020
  256. HARMAN S, Herten-Crabb A, Morgan R, Smith J, et al
    COVID-19 vaccines and women's security.
    Lancet. 2020 Dec 22. pii: S0140-6736(20)32727.
    PubMed    


  257. CLAESON M, Hanson S
    COVID-19 and the Swedish enigma.
    Lancet. 2020 Dec 22. pii: S0140-6736(20)32750.
    PubMed    


  258. SIVA N
    Experts call to include prisons in COVID-19 vaccine plans.
    Lancet. 2020;396:1870.
    PubMed    


  259. BURGESS RA, Osborne RH, Yongabi KA, Greenhalgh T, et al
    The COVID-19 vaccines rush: participatory community engagement matters more than ever.
    Lancet. 2020 Dec 10. pii: S0140-6736(20)32642.
    PubMed    


  260. DE COSTER I, Leroux-Roels I, Bandyopadhyay AS, Gast C, et al
    Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32541.
    PubMed     Abstract available


  261. SAEZ-LLORENS X, Bandyopadhyay AS, Gast C, Leon T, et al
    Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32540.
    PubMed     Abstract available


  262. THOMPSON KM
    Poliovirus vaccine options: another step forward.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
    PubMed    


  263. ARYEETEY E, Engebretsen E, Gornitzka A, Maassen P, et al
    A step backwards in the fight against global vaccine inequities.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32596.
    PubMed    


  264. KNOLL MD, Wonodi C
    Oxford-AstraZeneca COVID-19 vaccine efficacy.
    Lancet. 2020 Dec 8. pii: S0140-6736(20)32623.
    PubMed    


  265. VOYSEY M, Clemens SAC, Madhi SA, Weckx LY, et al
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
    Lancet. 2020 Dec 8. pii: S0140-6736(20)32661.
    PubMed     Abstract available


  266. USHER AD
    South Africa and India push for COVID-19 patents ban.
    Lancet. 2020;396:1790-1791.
    PubMed    


  267. THE LANCET
    An African plan to control COVID-19 is urgently needed.
    Lancet. 2020;396:1777.
    PubMed    


  268. MULHOLLAND K, Kretsinger K, Wondwossen L, Crowcroft N, et al
    Action needed now to prevent further increases in measles and measles deaths in the coming years.
    Lancet. 2020;396:1782-1784.
    PubMed    


    November 2020
  269. THE LANCET
    COVID-19 vaccines: no time for complacency.
    Lancet. 2020;396:1607.
    PubMed    


  270. RAMASAMY MN, Minassian AM, Ewer KJ, Flaxman AL, et al
    Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Lancet. 2020 Nov 18. pii: S0140-6736(20)32466.
    PubMed     Abstract available


  271. ANDREW MK, McElhaney JE
    Age and frailty in COVID-19 vaccine development.
    Lancet. 2020 Nov 18. pii: S0140-6736(20)32481.
    PubMed    


  272. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
    Lancet. 2020;396:1486-1487.
    PubMed    


  273. LODGE A
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lancet. 2020;396:1486.
    PubMed    


  274. CHAUHAN A, Agarwal A, Jaiswal N, Singh M, et al
    ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
    Lancet. 2020;396:1485-1486.
    PubMed    


  275. HORTON R
    Offline: Managing the COVID-19 vaccine infodemic.
    Lancet. 2020;396:1474.
    PubMed    


  276. SMITH MJ, Ujewe S, Katz R, Upshur REG, et al
    Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.
    Lancet. 2020 Nov 5. pii: S0140-6736(20)32337.
    PubMed    


  277. ANDERSON RM, Vegvari C, Truscott J, Collyer BS, et al
    Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
    Lancet. 2020 Nov 4. pii: S0140-6736(20)32318.
    PubMed    


    October 2020
  278. HASSAN-SMITH Z, Hanif W, Khunti K
    Who should be prioritised for COVID-19 vaccines?
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32224.
    PubMed    


  279. BINGHAM K
    The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world.
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32175.
    PubMed    


  280. KRAUSE PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, et al
    Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.
    Lancet. 2020 Oct 27. pii: S0140-6736(20)32259.
    PubMed    


  281. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    Use of adenovirus type-5 vectored vaccines: a cautionary tale.
    Lancet. 2020 Oct 19. pii: S0140-6736(20)32156.
    PubMed    


  282. WARD BJ, Makarkov A, Seguin A, Pillet S, et al
    Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (>/=65 years): two multicentre, randomised phase 3 trials.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32014.
    PubMed     Abstract available


  283. POLAND GA, Ovsyannikova IG, Kennedy RB
    SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32137.
    PubMed     Abstract available


  284. TREGONING JS
    First human efficacy study of a plant-derived influenza vaccine.
    Lancet. 2020 Oct 13. pii: S0140-6736(20)32010.
    PubMed    


  285. MCMAHON JH, Hoy JF, Kamarulzaman A, Bekker LG, et al
    Leveraging the advances in HIV for COVID-19.
    Lancet. 2020;396:943-944.
    PubMed    


    September 2020
  286. LOGUNOV DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV, et al
    Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31970.
    PubMed    


  287. PEIRIS M, Leung GM
    What can we expect from first-generation COVID-19 vaccines?
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31976.
    PubMed    


  288. BUCCI E, Andreev K, Bjorkman A, Calogero RA, et al
    Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
    Lancet. 2020 Sep 21. pii: S0140-6736(20)31960.
    PubMed    


  289. THE LANCET
    Global collaboration for health: rhetoric versus reality.
    Lancet. 2020;396:735.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: